After weighting, anti-IL5/IL5R therapy was associated with a significantly lower risk of congestive heart failure (aHR 0.63, 95% CI 0.52–0.76), arrythmia (aHR 0.78, 95% CI 0.68–0.90), and peripheral artery disease (aHR 0.69, 95% CI 0.54–0.87) compared with non-biologic users. Here, IL5RA is linked to congestive heart failure.